PCV13接种后侵袭性肺炎链球菌病流行病学变化
在疫苗接种覆盖率中等(<2岁儿童约64%)的西班牙加泰罗尼亚地区,分析2006-2014年监测数据发现,PCV13引入后侵袭性肺炎链球菌病(IPD)总发病率下降26.2%,主要因各年龄组PCV13血清型减少,提示群体免疫;但≥65岁成人非PCV13血清型上升13%,提示血清型替换。
要点
- PCV13期IPD总发病率较PCV7期下降26.2%(16.4降至12.1)。
- 2-4岁儿童IPD发病率降幅最大(44.5%,37.4降至20.8)。
- ≥65岁成人非PCV13血清型发病率上升13%(14.8升至16.8)。
核心结论
- 在疫苗接种覆盖率中等的地区,PCV13引入降低了IPD总发病率,主要归因于各年龄组PCV13血清型减少,提示群体免疫。
- ≥65岁成人非PCV13血清型增加,提示血清型替换。
研究设计与样本
- 分析2006-2014年加泰罗尼亚微生物报告系统中报告的IPD监测数据。
- 比较PCV7期(2006-2009)与PCV13期(2010-2014)间PCV7、PCV10non7、PCV13non10及非PCV13血清型的估计发病率比(IR)。
- 发病率按年份和年龄组(<2岁、2-4岁、5-64岁、≥65岁)校正缺失血清型。
主要发现
- 共报告9338例IPD病例。
- PCV13期整体IPD发病率下降26.2%(从16.4降至12.1)。
- 2-4岁儿童IPD发病率降幅最大(44.5%,从37.4降至20.8)。
- 肺炎在所有年龄组下降,2-4岁儿童降幅最大(49.3%),<2岁儿童降幅42%。
- PCV13血清型在所有年龄组显著下降,2-4岁儿童从52%降至15.1%(降幅31.6至15.1),≥65岁成人从35%降至14.8%(降幅22.8至14.8)。
临床怎么用
- 在覆盖率中等的地区,PCV13接种可降低各年龄组IPD发病率,应继续监测非PCV13血清型替换。
- 提高儿童PCV13接种覆盖率可能进一步降低所有年龄组的IPD发病率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). METHODS: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006-2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006-2009) and PCV13 periods (2010-2014). IR were corrected for missing serotypes according to year and age groups: <2 years, 2-4 years, 5-64 years and ≥65 years. RESULTS: A total of 9338 IPD cases were reported. Overall IPD incidence declined by 26.2% (from 16.4 to 12.1) in the PCV13 period. The largest decrease was observed in children aged 2-4 years (44.5%, from 37.4 to 20.8). Pneumonia fell in all age groups with the largest reduction in children aged 2-4 years (49.3%) and <2 years (42%). PCV13 serotypes decreased significantly in all age groups, from 52% (31.6 to 15.1) in children aged 2-4 years to 35% (22.8 to 14.8) in adults aged ≥65 years. Non-PCV13 serotypes rose by 13% (14.8 to 16.8) in people aged ≥65 years. CONCLUSIONS: In a region with intermediate vaccination coverage, the introduction of PCV13 has reduced the overall incidence of IPD, mainly due to the decrease in PCV13 serotypes in all age groups, suggesting herd immunity. Non-PCV13 serotypes have increased in adults aged ≥65 years, suggesting serotype replacement. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age groups.
引用
- Ciruela P, Izquierdo C, Broner S, et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine. 2018. PMID: 30473132. doi:10.1016/j.vaccine.2018.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。